D.E. Shaw & Co’s Jasper Therapeutics JSPR Stock Holding History

D.E. Shaw & Co’s Portfolio JSPR Stock Details JSPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-4,448	Closed	-$443K	–	5080
2021 Q2	$443K	Buy	+4,448	New	+$442K	﹤0.01%	4097

Other funds holding JSPR

Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

LPARFS

Leverage Partners Absolute Return Fund SPC Cayman Islands Ky1-11111, Cayman Islands $54K AUM

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

D.E. Shaw & Co's JSPR Position: Q3 2021 in Review

D.E. Shaw & Co sold out of Jasper Therapeutics (JSPR) in Q3 2021, closing a stake of 4,448 shares — an estimated $443K sold.

D.E. Shaw & Co first reported a position in JSPR in Q2 2021 and held it in 1 quarter. The position peaked at $443K in Q2 2021. 10 funds tracked by Wall St. Rank hold JSPR as of Q3 2021.

D.E. Shaw & Co reported no remaining Jasper Therapeutics position as of Q3 2021 after selling out during the quarter.
D.E. Shaw & Co sold 4,448 Jasper Therapeutics shares in Q3 2021, an estimated $443K.
D.E. Shaw & Co first reported a position in Jasper Therapeutics in Q2 2021 and held it in 1 quarter.
D.E. Shaw & Co's Jasper Therapeutics position peaked at $443K in Q2 2021.
10 funds tracked by Wall St. Rank held Jasper Therapeutics as of Q3 2021.

Based on D.E. Shaw & Co's 13F filing for Q3 2021, filed 15 Nov 2021.